Comportamiento de hemoglobina glicosilada y frecuencia de hipoglicemias en diabéticos tipo 2 tratados con insulina glargina o NPH

Rivera Toquica, Alex; Álvarez Vera, Tatiana; Ochoa Jaramillo, Francisco.
Rev. med. Risaralda ; 21(2): 3-10, jul.-dic. 2015. graf, tab
Artículo en Español | LILACS | ID: lil-776355

Documentos relacionados

  1. Loose-control of diabetes mellitus with protamine zinc insulin in cats: 185 cases (2005-2015).
  2. The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range.
  3. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
  4. Loose control of diabetes mellitus with protamine zinc insulin in cats.
  5. Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.
  6. Comparative effectiveness and safety of different basal insulins in a real-world setting.
  7. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
  8. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
  9. Assessment of Regular and NPH Insulin Concentration via Two Methods of Quantification: The Washington State Insulin Concentration Study (WICS).
  10. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.